SLC18A2 and Parkinson disease: Since more than 90% of VMAT2 locate in the dopamine nerve terminals [1], the in vivo estimation of VMAT2 density may have great help for the diagnosis and management of disorders associated with nigrostriatal degeneration, such as Parkinson's disease (PD).